NCT02641522View on ClinicalTrials.gov

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 8, 2016

Primary Completion Date

March 16, 2017

Study Completion Date

March 16, 2017

Conditions
Type 1 Diabetes
Interventions
DRUG

Siltuximab

Single infusion of siltuximab (11 mg/kg)

Trial Locations (1)

98101

Benaroya Research Institute, Seattle

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Carla Greenbaum, MD

OTHER

NCT02641522 - Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes | Biotech Hunter | Biotech Hunter